Trials / Terminated
TerminatedNCT00170742
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 17 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide, 30 mg i.m. LAR formulation |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-05-01
- First posted
- 2005-09-15
- Last updated
- 2008-08-12
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00170742. Inclusion in this directory is not an endorsement.